Loading...
iBio Q3 2025 Earnings Report
iBio reported its fiscal third quarter 2025 financial results, highlighting progress in its pipeline and a strengthened financial position.
Key Takeaways
iBio reported a net loss of $4.9 million for the fiscal third quarter ended March 31, 2025, compared to a net loss of $2.6 million in the same period last year. The company strengthened its financial position with a $6.2 million warrant inducement equity raise in April, and reported positive non-human primate data for IBIO-600 and in-licensed a first-in-class Activin E antibody.
Net loss from continuing operations was approximately $4.9 million, or $0.49 per share, for the three months ending March 31, 2025.
Research and Development (R&D) expenses increased to $1.9 million, up from $0.9 million in the prior year, driven by advancements in IBIO-600 and Activin E programs.
General and Administrative (G&A) expenses rose to approximately $3.0 million from $2.7 million, mainly due to IT-related costs, consulting fees, and franchise taxes.
Cash, cash equivalents, and restricted cash stood at approximately $5.2 million as of March 31, 2025, and increased to $10.5 million as of May 1, 2025, following a warrant inducement transaction.
iBio
iBio
Forward Guidance
iBio is positioned for continued growth and aims for regulatory submission of IBIO-600 in 2026, leveraging its strengthened financial position and pipeline advancements.
Positive Outlook
- Strengthened financial position with a $6.2 million warrant inducement equity raise.
- Progress towards regulatory submission of IBIO-600 in 2026.
- Promising non-human primate data for IBIO-600, indicating extended half-life and dose-dependent muscle growth.
- In-licensed a first-in-class Activin E antibody, expanding the cardiometabolic and obesity pipeline.
- Nasdaq listing enhances visibility and improves trading liquidity, attracting long-term institutional investors.
Challenges Ahead
- Actual results may differ materially from forward-looking statements.
- Ability to successfully develop IBIO-600 and Activin E antibody is not guaranteed.
- Ability to attract long-term institutional investors is subject to market conditions.
- Ability to finance when needed is a risk factor.
- Risk factors described in the Company's Annual Report on Form 10-K for the year ended June 30, 2024, and subsequent filings.